Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT003 is a needle-free local anesthetic gel currently in preclinical development by **Cessatech**, a Danish pharmaceutical company specializing in pediatric pain management. The drug is specifically designed for application to open wounds, such as those encountered during pediatric laceration repair in emergency settings, to provide effective analgesia without the psychological and physical distress of needle-based administration. CT003 functions as a small molecule inhibitor that blocks **voltage-gated sodium channels (Nav)**, thereby inhibiting nerve conduction and providing localized pain relief. It is being developed as a follow-on product to the company's lead asset, CT001, to address the unmet medical need for approved local anesthetic combinations suitable for direct application to open wounds in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CT003.